Skip to Content
  • Previous Rank
    11
  • Revenues ($M)
    $208,357
  • Revenue Percent Change
    4.9%
  • Profits ($M)
    $67
  • Profits Percent Change
    -98.7%
  • Assets ($M)
    $60,381.00
  • Employees
    68,000

America’s largest pharmaceutical distributor slips two spots on the Global 500 this year, but the continued strength of its distribution business—serving as the middleman between manufacturers and pharmacies—lifted revenues 4.9%. The acquisition of Rexall Health powered some of that growth as did trends like the nation’s climbing drug prices and rising drug utilization rates. McKesson also moved ahead with its plan to divest its technology businesses in deals with Change Healthcare and Allscripts. The company, along with the country’s other large drug distributors, remains a target of litigation over its alleged role in the nation’s opioid epidemic.

Company Information

Figures are for fiscal year ended March 31, 2018.
CEO
John H. Hammergren
Sector
Wholesalers
Industry
Wholesalers: Health Care
HQ Location
San Francisco
Websitehttp://www.mckesson.com
Years on Global 500 List24
Employees68,000

McKesson Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$208,3574.9%
Profits ($M)$67-98.7%
Assets ($M)$60,381.00-
Total Stockholder Equity ($M)$9,804.00-

Profit Ratios

Profit as % of Revenues-
Profits as % of Assets0.1%
Profits as % of Stockholder Equity0.7%